定量冷冻喷雾治疗慢阻肺慢性支气管炎的前瞻性安全性与可行性研究
本研究评估定量冷冻喷雾(MCS)治疗慢阻肺慢性支气管炎的可行性、疗效与安全性,纳入35例FEV1占预计值30-80%的患者。34例完成三次治疗,3个月时SGRQ、CAT和LCQ均出现临床意义改善,至12个月记录14例严重不良事件,无器械或操作相关严重不良事件。结论认为MCS安全、可行并改善多维患者报告结局。
要点
- MCS治疗慢阻肺慢性支气管炎可行,34/35例完成三次治疗。
- 3个月时SGRQ、CAT、LCQ均较基线有临床意义改善。
- 12个月时11例(31.4%)报告14例严重不良事件,无器械或操作相关。
核心结论
- MCS对慢阻肺慢性支气管炎患者安全、可行,并与多维患者报告结局的临床意义改善相关。
研究设计与样本
- 前瞻性安全性与可行性研究,纳入FEV1占预计值30-80%且接受优化药物治疗的慢阻肺慢性支气管炎患者35例。
主要发现
- 34例完成三次液氮治疗,每次持续34.3±12.1分钟,间隔4-6周,共递送约1800剂MCS。
- 3个月时SGRQ变化-6.4(95%CI -11.4至-1.3;p=0.01),CAT变化-3.8(95%CI -6.4至-1.3;p<0.01),LCQ变化21.6(95%CI 7.3至35.9;p<0.01)。
- CAT改善持续至6个月(-3.4,95%CI -5.9至-0.9;p=0.01),SGRQ和LCQ改善持续至9个月(分别为-6.9,95%CI -13.0至-0.9;p=0.03和13.4,95%CI 2.1至24.6;p=0.02)。
- 12个月时11例(31.4%)受试者记录14例严重不良事件,其中6例(43%)为中度、8例(57%)为重度;9例呼吸相关(6例慢阻肺急性加重、2例肺炎、1例咳嗽加重),均无后遗症恢复,无器械或操作相关严重不良事件。
临床怎么用
- 对于优化药物治疗后仍有慢性支气管炎症状的慢阻肺患者,MCS可能作为改善患者报告结局的干预选择。
- 治疗需分三次进行,间隔4-6周,每次约34分钟,需关注呼吸相关严重不良事件。
局限性
- 研究为前瞻性单臂设计,样本量35例,缺乏对照组,可行性与安全性结论需更大规模对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No currently approved intervention counteracts airway metaplasia and mucus hypersecretion of chronic bronchitis in COPD. However, metered cryospray (MCS) delivering liquid nitrogen to the tracheobronchial airways ablates abnormal epithelium and facilitates healthy mucosal regeneration. The objective of this study was to evaluate the feasibility, efficacy and safety of MCS in chronic bronchitis. METHODS: Patients with a forced expiratory volume in 1 s of 30-80% predicted who were taking optimal medication were recruited. Primary outcomes were feasibility (completion of treatments), efficacy (3-month change in St George's Respiratory Questionnaire (SGRQ)) and safety (incidence of adverse events). Secondary outcomes were lung function, exercise capacity and additional patient-reported outcomes. RESULTS: 35 patients, 19 male/16 female, aged 47-76 years, Global Initiative for Chronic Obstructive Lung Disease grade I (n=3), II (n=10) and III (n=22), underwent staggered liquid nitrogen treatments to the tracheobronchial tree. 34 patients completed three treatments, each lasting 34.3±12.1 min, separated by 4-6 weeks; one withdrew after the first treatment. ∼1800 doses of MCS were delivered. Clinically meaningful improvements in patient-reported outcomes were observed at 3 months: change in SGRQ -6.4 (95% CI -11.4 to -1.3; p=0.01), COPD Assessment Test (CAT) -3.8 (95% CI -6.4 to -1.3; p<0.01) and Leicester Cough Questionnaire (LCQ) 21.6 (95% CI 7.3 to 35.9; p<0.01). Changes in CAT were durable to 6 months (-3.4, 95% CI -5.9 to -0.9; p=0.01); changes in SGRQ and LCQ were durable to 9 months (-6.9, 95% CI -13.0 to -0.9; p=0.03 and 13.4, 95% CI 2.1 to 24.6; p=0.02, respectively. At 12 months, 14 serious adverse events were recorded in 11 (31.4%) subjects; six (43%) moderate and eight (57%) severe. Nine were respiratory-related: six exacerbations of COPD, two pneumonias and one case of increased coughing; all recovered without sequelae. None were serious device- or procedure-related adverse events. CONCLUSION: MCS is safe, feasible and associated with clinically meaningful improvements in multidimensional patient-reported outcomes.
引用
- Garner JL, Shaipanich T, Hartman JE, et al. A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD. Eur Respir J. 2020. PMID: 32586881. doi:10.1183/13993003.00556-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。